Lipoprotein lipase Activator NO-1886

NO-1886 increases LPL mRNA and LPL activity in adipose tissue, myocardium and skeletal muscle, resulting in an elevation of postheparin plasma LPL activity and LPL mass in rats. NO-1886 also decreasess plasma TG concentration and causes a concomitant rise in plasma HDL-C, reduces plasma glucose, improves insulin resistance and β-cell dysfunction. Therefore, the LPL activator NO-1886 or other possible LPL activating agents are potentially beneficial for the treatment of hypertriglyceridemia, hypo-HDL cholesterolemia, and protection from atheroscleroosis and diabetes.